At the close on September 7, 2026, Pfizer stock hovered around the USD 28 mark on the NYSE with limi

Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are building a separate case altogether for investors willing to look past the dividend.

Following the approval, Novartis India signed an asset purchase agreement and trademark assignment deeds: Reports

The pharmaceutical stock is struggling, but its dividend can be highly valuable to income investors.

Novartis India acquires BP drug trademarks from Pfizer for ₹1,250 crore, following ChrysCapital's stake acquisition.

Novartis India Ltd, controlled by homegrown private equity firm ChrysCapital, has inked a deal to acquire Pfizer’s blood pressure medication brand...

The company's board approved the transaction on Monday, following which Novartis India executed an asset purchase agreement and trademark assignment deeds with Pfizer Inc and Pfizer Products Inc

Novartis India will acquire Pfizer's Minipress and Minipres trademarks in India for Rs 1,250 crore, as Pfizer exits the hypertension drug.

Pfizer Inc. stock reflects a mix of strategic portfolio moves and solid Q2 2026 earnings. Investors

Novartis India Limited has announced the acquisition of the ‘Minipress’ and ‘Minipres’ trademarks in India , along with certain related intellectual property…

Pfizer Limited will discontinue Minipress XL after Pfizer Inc. USA decided to stop manufacturing the product, with the Indian company set to receive a lump sum payment of around Rs 131.38 crore.

Novartis India will acquire trademarks registered in India and certain related intellectual property rights for Rs 1,250 crore

The company has executed an asset purchase agreement and trademark assignment deeds with Pfizer Inc USA and Pfizer Products Inc USA

Novartis India acquires Minipress brand from Pfizer for ₹1,250 crore. Learn about the deal details, brand revenue, valuation, and potential risks for investors.

Novartis India will acquire the Minipress and Minipres trademarks and related intellectual property from Pfizer for about ₹1,250 crore. Minipress XL, used for hypertension and benign prostatic hyperplasia, generated ₹228.6 crore in revenue as of July 2026, according to IQVIA data.

Pfizer Limited ends Minipress XL sale operations, receives USD 13.9 million payout from Pfizer Inc. USA post manufacturing halt.